Zentalis Pharmaceuticals, Inc. (ZNTL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.7 |
| Open | 4.71 |
| Day High | 4.91 |
| Day Low | 4.29 |
| 52-Week High | 6.95 |
| 52-Week Low | 1.21 |
| Volume | 1.4M |
| Average Volume | 1.32M |
| Market Cap | 347.39M |
| PE | -2.82 |
| EPS | -1.73 |
| Moving Average 50 Days | 4.04 |
| Moving Average 200 Days | 2.7 |
| Change | 0.18 |
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Feb 03, 2026 9:05 PM GMT
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial pl
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin